On the public citation graph
Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir
0 signed · 114 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.26141openalex-snapshot
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
inferredcites →https://doi.org/10.1002/hep.27053openalex-snapshot
All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection
inferredcites →https://doi.org/10.1002/hep.27113openalex-snapshot
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
inferredcites →https://doi.org/10.1002/jmv.24255openalex-snapshot
Long term persistence of NS5A inhibitor‐resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy
inferredcites →https://doi.org/10.1006/bbrc.1994.2667openalex-snapshot
Production of Two Phosphoproteins from the NS5A Region of the Hepatitis C Viral Genome
inferredcites →https://doi.org/10.1006/viro.1997.8493openalex-snapshot
Evidence That Hepatitis C Virus Resistance to Interferon Is Mediated through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein
inferredcites →https://doi.org/10.1016/j.jcv.2011.08.015openalex-snapshot
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
inferredcites →https://doi.org/10.1016/j.jcv.2012.04.024openalex-snapshot
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
inferredcites →https://doi.org/10.1016/j.jhep.2011.12.029openalex-snapshot
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
inferredcites →https://doi.org/10.1016/j.jhep.2014.11.032openalex-snapshot
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
inferredcites →https://doi.org/10.1016/s0140-6736(13)62121-2openalex-snapshot
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
inferredcites →https://doi.org/10.1016/s0140-6736(14)61059-xopenalex-snapshot
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
inferredcites →https://doi.org/10.1016/s0140-6736(14)61795-5openalex-snapshot
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis…
inferredcites →https://doi.org/10.1016/s0168-8278(12)61184-2openalex-snapshot
1172 ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885
inferredcites →https://doi.org/10.1016/s0168-8278(13)60015-xopenalex-snapshot
13 COMBINATION OF THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, AND PEGYLATED INTERFERON PLUS RIBAVIRIN IN TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION
inferredcites →https://doi.org/10.1016/s0168-8278(13)60066-5openalex-snapshot
64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS
inferredcites →https://doi.org/10.1016/s0168-8278(15)30071-4openalex-snapshot
O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens
inferredcites →https://doi.org/10.1016/s0168-8278(99)80374-2openalex-snapshot
Molecular virology of the hepatitis C virus
inferredcites →https://doi.org/10.1021/jm401398xopenalex-snapshot
Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
inferredcites →https://doi.org/10.1038/srep04765openalex-snapshot
Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA
inferredcites →https://doi.org/10.1053/j.gastro.2014.04.021openalex-snapshot
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
inferredcites →https://doi.org/10.1053/j.gastro.2016.06.002openalex-snapshot
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
inferredcites →https://doi.org/10.1056/nejmoa1306218openalex-snapshot
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
inferredcites →https://doi.org/10.1056/nejmoa1316366openalex-snapshot
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
inferredcites →https://doi.org/10.1056/nejmra1213651openalex-snapshot
Current and Future Therapies for Hepatitis C Virus Infection
inferredcites →https://doi.org/10.1074/jbc.m112.376822openalex-snapshot
Correlation between NS5A Dimerization and Hepatitis C Virus Replication
inferredcites →https://doi.org/10.1093/cid/cit226openalex-snapshot
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
inferredcites →https://doi.org/10.1111/jvh.12405openalex-snapshot
Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy
inferredcites →https://doi.org/10.1126/science.285.5424.110openalex-snapshot
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
inferredcites →https://doi.org/10.1128/aac.00307-11openalex-snapshot
Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
inferredcites →https://doi.org/10.1128/aac.00556-10openalex-snapshot
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
inferredcites →https://doi.org/10.1128/aac.02193-12openalex-snapshot
Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885
inferredcites →https://doi.org/10.1128/aac.02494-12openalex-snapshot
Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir
inferredcites →https://doi.org/10.1128/aac.04958-14openalex-snapshot
Cyclophilin and NS5A Inhibitors, but Not Other Anti-Hepatitis C Virus (HCV) Agents, Preclude HCV-Mediated Formation of Double-Membrane-Vesicle Viral Factories
inferredcites →https://doi.org/10.1128/jvi.01319-10openalex-snapshot
Hepatitis C Virus Nonstructural Protein 5A: Biochemical Characterization of a Novel Structural Class of RNA-Binding Proteins
inferredcites →https://doi.org/10.1128/jvi.02294-12openalex-snapshot
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
inferredcites →https://doi.org/10.1128/jvi.02995-14openalex-snapshot
Serine Phosphorylation of the Hepatitis C Virus NS5A Protein Controls the Establishment of Replication Complexes
inferredcites →https://doi.org/10.1371/journal.pone.0041191openalex-snapshot
Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
inferredcites →https://doi.org/10.1371/journal.pone.0122844openalex-snapshot
Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
inferredcites →https://doi.org/10.1371/journal.ppat.1000035openalex-snapshot
Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly
inferredcites →https://doi.org/10.3851/imp2729openalex-snapshot
Virological Escape in HCV Genotype-1-Infected Patients Receiving Daclatasvir plus Ribavirin and Peginterferon Alfa-2A or Alfa-2B
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4613660openalex-extracted
Prevalence of Drug Resistance Associated Substitutions in Hepatitis C-Infected Patients Whose WHO-Recommended Direct Acting Agents for Initial Treatment and Retreatment Fails: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/9781683670438.mcm0115openalex-snapshot
Mechanisms of Resistance to Antiviral Agents
inferred← citeshttps://doi.org/10.1002/9781683674849.mcm0115openalex-snapshot
Mechanisms of Resistance to Antiviral Agents
inferred← citeshttps://doi.org/10.1002/hep.30126openalex-snapshot
Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis
inferred← citeshttps://doi.org/10.1002/hep4.1496openalex-snapshot
Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
inferred← citeshttps://doi.org/10.1002/jmv.29103openalex-snapshot
Construction and characterization of a new hepatitis C virus genotype 6a subgenomic replicon that is prone to render the sofosbuvir resistance
inferred← citeshttps://doi.org/10.1002/ygh2.329openalex-snapshot
Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-03757-4_2openalex-snapshot
Laboratory and Molecular Diagnosis of Hepatitis C and Resistance Testing
inferred← citeshttps://doi.org/10.1007/978-3-030-03757-4_8openalex-snapshot
Management of Interferon-Free Direct-Acting HCV Antiviral Therapy Failure
inferred← citeshttps://doi.org/10.1007/s11901-018-0395-9openalex-snapshot
Treatment of DAA-Experienced Patients with Chronic Hepatitis C
inferred← citeshttps://doi.org/10.1007/s11904-017-0369-5openalex-snapshot
Resistance to DAAs: When to Look and When It Matters
inferred← citeshttps://doi.org/10.1016/b978-0-443-41363-6.00013-5openalex-snapshot
Antiviral resistance in hepatitis C and DAA therapy
inferred← citeshttps://doi.org/10.1016/b978-84-9113-949-2.00080-9openalex-snapshot
10.1016/b978-84-9113-949-2.00080-9
inferred← citeshttps://doi.org/10.1016/j.antiviral.2018.08.001openalex-snapshot
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China
inferred← citeshttps://doi.org/10.1016/j.antiviral.2020.104871openalex-snapshot
Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors
inferred← citeshttps://doi.org/10.1016/j.antiviral.2021.105224openalex-snapshot
Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance
inferred← citeshttps://doi.org/10.1016/j.dld.2017.11.013openalex-snapshot
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review
inferred← citeshttps://doi.org/10.1016/j.ijantimicag.2018.10.005openalex-snapshot
Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance
inferred← citeshttps://doi.org/10.1016/j.jgar.2021.01.012openalex-snapshot
Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours
inferred← citeshttps://doi.org/10.1016/j.jhep.2018.07.023openalex-snapshot
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients
inferred← citeshttps://doi.org/10.1016/j.jhep.2019.07.020openalex-snapshot
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure
inferred← citeshttps://doi.org/10.1016/j.jhep.2020.11.017openalex-snapshot
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
inferred← citeshttps://doi.org/10.1016/j.jhep.2021.03.004openalex-snapshot
Treatment failure with DAA therapy: Importance of resistance
inferred← citeshttps://doi.org/10.1016/j.jhep.2021.04.057openalex-snapshot
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.08.016openalex-snapshot
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
inferred← citeshttps://doi.org/10.1016/j.jhepr.2022.100462openalex-snapshot
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
inferred← citeshttps://doi.org/10.1016/j.jhepr.2023.100994openalex-snapshot
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure
inferred← citeshttps://doi.org/10.1016/j.jinf.2019.10.007openalex-snapshot
Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group
inferred← citeshttps://doi.org/10.1016/j.meegid.2024.105653openalex-snapshot
Hepatitis C virus subtype distribution and resistance-associated substitutions in high-risk population groups in Guangdong Province, China
inferred← citeshttps://doi.org/10.1016/j.talanta.2024.125754openalex-snapshot
Catalytic hairpin assembly triggering amplified DNAzyme-feedback for sensitive detection of hepatitis C virus genotype 1b
inferred← citeshttps://doi.org/10.1038/s41575-022-00608-8openalex-snapshot
Breakthroughs in hepatitis C research: from discovery to cure
inferred← citeshttps://doi.org/10.1053/j.gastro.2018.10.024openalex-snapshot
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges
inferred← citeshttps://doi.org/10.1080/10408363.2019.1637394openalex-snapshot
Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes?
inferred← citeshttps://doi.org/10.1080/14787210.2018.1538783openalex-snapshot
Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options
inferred← citeshttps://doi.org/10.1080/14787210.2024.2328336openalex-snapshot
Personalized care approaches to hepatitis C therapy: recent advances and future directions
inferred← citeshttps://doi.org/10.1080/17474124.2019.1651642openalex-snapshot
Management of HCV patients in cases of direct-acting antiviral failure
inferred← citeshttps://doi.org/10.1080/23808993.2020.1764346openalex-snapshot
The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities
inferred← citeshttps://doi.org/10.1089/mdr.2018.0360openalex-snapshot
Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection
inferred← citeshttps://doi.org/10.1093/cid/ciaa1510openalex-snapshot
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry
inferred← citeshttps://doi.org/10.1093/cid/ciae431openalex-snapshot
Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis
inferred← citeshttps://doi.org/10.1111/apt.14650openalex-snapshot
Editorial: retreatment of DAA ‐failures—no problem at all?
inferred← citeshttps://doi.org/10.1111/jvh.12734openalex-snapshot
No one size fits all—Shortening duration of therapy with direct‐acting antivirals for hepatitis C genotype 1 infection
inferred← citeshttps://doi.org/10.1111/jvh.13270openalex-snapshot
Prevalence of HCV resistance‐associated substitutions among treatment‐failure patients receiving direct‐acting antiviral agents
inferred← citeshttps://doi.org/10.1111/jvh.14058openalex-snapshot
Resistance‐Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC ‐ CANUHC Analysis
inferred← citeshttps://doi.org/10.1111/liv.14201openalex-snapshot
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse
inferred← citeshttps://doi.org/10.1128/aac.01280-18openalex-snapshot
In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A
inferred← citeshttps://doi.org/10.1128/aac.02217-17openalex-snapshot
Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan
inferred← citeshttps://doi.org/10.1186/s12879-017-2817-7openalex-snapshot
Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil
inferred← citeshttps://doi.org/10.1186/s12879-021-06080-0openalex-snapshot
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report
inferred← citeshttps://doi.org/10.1186/s12985-017-0760-2openalex-snapshot
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845
inferred← citeshttps://doi.org/10.1186/s12985-018-0936-4openalex-snapshot
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
inferred← citeshttps://doi.org/10.1186/s43066-024-00321-yopenalex-snapshot
Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs
inferred← citeshttps://doi.org/10.18470/1992-1098-2024-1-4openalex-snapshot
Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region
inferred← citeshttps://doi.org/10.21203/rs.3.rs-6534099/v1openalex-snapshot
Influence of quadruple-infected patients on the effectiveness of antiviral therapy and analysis of drug resistance sites
inferred← citeshttps://doi.org/10.2147/hmer.s55864openalex-snapshot
Interferon-free combination therapies for the treatment of hepatitis C: current insights
inferred← citeshttps://doi.org/10.22625/2072-6732-2018-10-4-30-36openalex-snapshot
Drug resistant variants of hepatitis C virus genotype 1b in Russia: analysis of aminoacid substitutions in NS5a and core proteins
inferred← citeshttps://doi.org/10.22625/2072-6732-2020-12-1-104-110openalex-snapshot
Eradication of hepatitits C virus in patient with cryoglobulinemic vasculitis and mutations D168E, L31V
inferred← citeshttps://doi.org/10.23736/s0026-4806.20.07208-0openalex-snapshot
Hepatitis C: clinical management and debated issues
inferred← citeshttps://doi.org/10.3138/canlivj.1.2.006openalex-snapshot
Remaining clinical issues in hepatitis C treatment
inferred← citeshttps://doi.org/10.33425/2639-9334.1042openalex-snapshot
Factors Associated with Treatment Failure for Hepatitis C in the Era of Direct-Acting Antivirals Therapy in Cameroon
inferred← citeshttps://doi.org/10.3389/fmicb.2017.01833openalex-snapshot
Long Non-coding RNAs in Hepatitis C Virus-Infected Cells
inferred← citeshttps://doi.org/10.3390/biomedicines8040080openalex-snapshot
Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C
inferred← citeshttps://doi.org/10.3390/biomedicines9101446openalex-snapshot
The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression
inferred← citeshttps://doi.org/10.3390/ijms27115068openalex-snapshot
A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity
inferred← citeshttps://doi.org/10.3390/pathogens13080674openalex-snapshot
An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences
inferred← citeshttps://doi.org/10.3390/v14010016openalex-snapshot
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures
inferred← citeshttps://doi.org/10.3748/wjg.v24.i38.4304openalex-snapshot
Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus
inferred← citeshttps://doi.org/10.3748/wjg.v26.i2.168openalex-snapshot
Assessment of lncRNA GAS5, lncRNA HEIH, lncRNA BISPR and its mRNA BST2 as serum innovative non-invasive biomarkers: Recent insights into Egyptian patients with hepatitis C virus type 4
inferred← citeshttps://doi.org/10.4103/jfmpc.jfmpc_943_19openalex-snapshot
Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
inferred← citeshttps://doi.org/10.4254/wjh.v10.i9.543openalex-snapshot
Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
inferred← citeshttps://doi.org/10.4274/vhd.galenos.2023.2023-8-4openalex-snapshot
Drug Resistance to HCV in Direct-Acting Antiviral Treatments
inferred← citeshttps://doi.org/10.6084/m9.figshare.14490085openalex-snapshot
Additional file 1 of Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.